Saudi Arabia Mental Health Surveillance System (MHSS): mental health trends amid COVID-19 and comparison with pre-COVID-19 trends

Nasser F. BinDhim a,b,c, Nora A. Althumiri d, Mada H. Basyouni e,f,g, Asem A. Alageel h,i, Suliman Alghnmi j, Ada M. Al-Qunaibet k, Rasha A. Almubarak l,m,n, Shahla Aldhukair o, and Yasser Ad-Dab’bagh p,q

*Scientific Affairs Department, Sharik Association for Health Research, Riyadh, Saudi Arabia; bCEO Office, Saudi Food and Drug Authority, Riyadh, Saudi Arabia; cPublic Health Department, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; dSmall and medium enterprises Department, Ministry of Health, Riyadh, Saudi Arabia; eDepartment of Clinical Neurosciences, College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia; fPopulation Health Department, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; gPublic Health Research and Health Statistics Department, The National Center for Disease Prevention and Control (Waqaya), Riyadh, Saudi Arabia; hResearch and Studies Department, Saudi Health Council, Riyadh, Saudi Arabia; iMental Health Department, King Fahd Specialist Hospital, Dammam, Saudi Arabia

ABSTRACT

Background: The impact of the COVID-19 pandemic on populations’ mental health has started to emerge.

Objectives: To describe the mental health trends of the risk of major depressive disorder (MDD) and generalized anxiety disorder (GAD) between May and August 2020. It also compares the results with pre-COVID-19 results and identifies risk factors associated with increased likelihood of being at risk of MDD and GAD.

Method: This study utilizes repeated cross-sectional design, at national-level coverage of mental health screenings via computer-assisted phone interviews conducted in four waves monthly (between May and August 2020). Arabic-speaking adults from Saudi Arabia were recruited via a random phone list. The questionnaire includes the Arabic version of the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7). Pre-COVID-19 comparison was done using the PHQ-2 score to allow for comparison with a previous and similar national study conducted in 2018.

Results: Across the four waves, 16,513 participants completed the interviews, with an overall response rate of 81.3%. The weighted national prevalence of people at risk of MDD was 14.9% overall, and 13.8%, 13.6%, 16.8%, and 15.3% in Waves 1, 2, 3, and 4, respectively. The weighted national prevalence of people at risk of GAD was 11.4%, overall, and 10.9%, 10.7%, 12.4%, and 11.7% in Waves 1, 2, 3, and 4, respectively. The weighted national proportion of individuals who were at risk of MDD and GAD at the same time was 7.4% overall. The risk of MDD on PHQ-2 increased by 71.2%, from 12.5% in 2018 to 21.4% in 2020.

Conclusions: The risks of MDD and GAD in this study are relatively high. These results can help decision makers to understand the impact of the COVID-19 pandemic on the population’s mental health and the most-impacted subgroups.

Sistema de Vigilancia de Salud Mental de Arabia Saudita (MHSS): Tendencias de salud mental durante la pandemia COVID-19 y comparación con las tendencias pre COVID-19

Antecedentes: El impacto de la pandemia COVID-19 en la salud mental de la población ha comenzado a emerger.

Objetivos: Describir las tendencias en salud mental del riesgo de tener un trastorno depresivo mayor (MDD por sus siglas en inglés) y un trastorno de ansiedad generalizado (GAD por sus siglas en inglés) entre Mayo y Agosto de 2020. También compara los resultados con los resultados de COVID-19 e identifica factores de riesgo asociados con el aumento de la probabilidad de estar en riesgo de sufrir MDD y GAD

Método: Este estudio utiliza un diseño transversal replicado, a un nivel de cobertura nacional de tamizaje sobre salud mental vía entrevistas telefónicas asistidas por computador, conducidas en 4 olas mensualmente (entre Mayo y agosto de 2020). Adultos que hablaban árabe de Arabia Saudita fueron reclutados mediante una lista aleatoria de teléfonos. El cuestionario incluía la versión árabe del Cuestionario de Salud del Paciente (PHQ-9) y de La Escala del Trastorno de Ansiedad Generalizada (GAD-7). Se hicieron comparaciones pre-COVID-19 usando el puntaje del PHQ-2 para permitir la comparación con un estudio previo nacional de características similares que fue realizado el 2018.

Resultados: A través de las cuatro olas, 16,513 participantes completaron las entrevistas, con una tasa de respuesta promedio de 81.3%. La prevalencia nacional calculada de personas en riesgo para MDD fue de 14.9% en general y de 13.8%, 13.6%, 16.8% y 15.3% en Olas 1, 2, 3 y 4 respectivamente. La prevalencia nacional calculada de personas en riesgo...
para GAD fue 11.4% en general y 10.9%, 10.7%, 12.4% y 11.7% en Olas 1, 2, 3 y 4 respectivamente. La proporción nacional calculada de individuos que estaban en riesgo para MDD y GAD al mismo tiempo fue de 7.4% en general. El riesgo de MDD según el PHQ-2 aumentó en un 71.2%, de 12.5% en 2018 a 21.4% en 2020.

## Conclusiones
El riesgo de MDD y GAD encontrado en este estudio es relativamente alto. Estos resultados pueden ayudar a entender a las personas que toman decisiones del impacto de la pandemia COVID-19 en la salud mental de la población y en los subgrupos más impactados.

###沙特阿拉伯心理健康监测系统 (MHSS): COVID-19中的心理健康趋势以及与COVID-19之前趋势的比较

**背景:**COVID-19疫情对人们心理健康的影响开始逐渐显现。本研究利用重复的横断面设计，通过2020年5月至8月每月进行的四次计算机辅助电话访谈，在全国范围内进行心理健康筛查。通过随机电话列表招募了沙特阿拉伯中说阿拉伯语的成人，问卷包括阿拉伯语版的患者健康问卷 (PHQ-9) 和广泛性焦虑障碍量表 (GAD-7)。将这些结果与COVID-19之前的比较使用了PHQ-2评分，以便与2018年进行的前人的类似国家研究进行比较。

**结果:**在这四次测量中，16,513名参与者完成了访谈。总回应率为81.3%。MDD风险人群的加权全国患病率总体上为14.9%，在第1、2、3和4次测量中分别为13.8%、13.6%、16.8%和15.3%。GAD风险人群的加权全国患病率总体上为11.4%，第1、2、3和4次分别10.9%、10.7%、12.4%和11.7%。同时为MDD和GAD的危险人群的加权全国比例总计为17.4%。PHQ-2的MDD风险从2018年的12.4%增加到2020年的21.4%，增加了21.2%。

**结论:**本研究中MDD和GAD的风险较高。这些结果可以帮助决策者了解COVID-19疫情对人群心理健康和受影响最大亚群的影响。

###1. Introduction

As it was increasingly exposed to the COVID-19 disease and its socioeconomic and health consequences, the general population became vulnerable to the psychological impacts of COVID-19 (Lee, 2020). Psychological distress may have been caused by the restriction of individual movement and social interaction, economic impacts and job loss, fear of getting COVID-19 oneself and/or giving it to loved ones, infection or death of a close individual or loved one due to COVID-19, media and news circulation of stressful information about COVID-19, and more known or unknown factors (Serafini et al., 2020). Many international and local health authorities, as well as scientific circulations issued, call for immediate prioritization and collection of high-quality data on the mental health effects of the COVID-19 pandemic across the population and vulnerable groups (Althumiri et al., 2018; Holmes et al., 2020; Javakhishvili et al., 2020; Olff et al., 2020). By mid-2020, evidence of the COVID-19 period’s effect on mental health were starting to emerge (McGinty, Presskreischer, Han, & Barry, 2020; Pierce et al., 2020).

Traditionally, social life in Saudi Arabia has revolved around the family and social gatherings; family visits and events are very common (Yezli & Khan, 2020). Religion is another major pillar of Saudi society, and groups in mosques typically hold five group prayers each day (Yezli & Khan, 2020). Group prayers in mosques are also a kind of social gathering where neighbours socialize.

On the 2nd of March 2020, the Saudi authorities reported the first case of COVID-19. As COVID-19 continued to spread, the Saudi government enforced many drastic measures, for the first time in many decades, to curb the disease, including partial and 24-hour lockdowns, suspension of religious activities such as prayer in mosques, and Umrah mass gatherings (Ebrahim & Memish, 2020; Yezli & Khan, 2020). Consequently, as in many countries globally, the economic impact of the lockdown affected many businesses in Saudi Arabia, leading to lost jobs or cuts to monthly salaries. Moreover, the government increased the value-added tax (VAT) by 10% from 5% to 15% starting from the 1st of July 2020. In general, the complete (24 hours) or partial (usually starting at 3 pm to 6 am) lockdown in Saudi Arabia lasted around 3 months, between mid-March 2020 and the end of May 2020, and for some cities and business activities, the lockdown continued until the end of June 2020.

Public health surveillance is one of the keystones of public health practice, empowering decision makers to lead and manage public health programmes more effectively by providing timely and useful information and evidence (Thacker, Qualters, & Lee, 2012). Public health surveillance is defined as ‘the systematic, ongoing collection, management, analysis, and interpretation of data, followed by timely dissemination of these data to public health programs to stimulate public health action’ (Porta, 2014). Mental health surveillance systems data can be used to track trends in mental
illness and psychological distress associated with exposure to traumatic events, such as military combat, or large-scale disasters, such as COVID-19 (Norris, 2006; Olff et al., 2020; Reeves, Pratt, & Thompson et al., 2011). Surveillance data are vital to the public health goals of reducing the incidence, prevalence, severity, and economic impact of mental conditions via providing timely signals to decision makers and establishing opportunities for early intervention. (BinDhim et al., 2020). Mental health screening tools are now included in the most established health surveillance surveys, such as the Centers for Disease Control and Prevention’s (CDC) National Health Interview Survey (NHIS) and the Behavioural Risk Factor Surveillance System (BRFSS), which highlights the importance of mental health surveillance for the general population (Colpe et al., 2010).

Although some published peer-reviewed scientific articles have looked at the prevalence of mental health conditions in Saudi Arabia, none of these were conducted with the benefit of larger national coverage, with most focusing on specific samples, such as university students or hospital visitors (Al-Gelban, Al-Amri, & Mostafa, 2009; Al-Qadhi, Ur Rahman, Ferwana, & Abdulmajeed, 2014; Ibrahim, Dania, Lamis, Ahd, & Asali, 2013). However, the Saudi Food and Drug Authority reported the prevalence of risk of depression on a national level as part of the Saudi Health, Diet, and Physical Activity national survey, which provided a prevalence on the Patient Health Questionnaire-2 (PHQ-2) of 12.5% out of 3,698 participants from the 13 administrative regions of Saudi Arabia (Althumiri et al., 2018; Arroll et al., 2010). However, on an international level, some data are currently available from the UK and the USA that demonstrate the impact of COVID-19 on population mental health (McGinty et al., 2020; Pierce et al., 2020). In the UK, clinically significant levels of mental distress rose from 18.9% in 2018 to 27.3% in April 2020.(7) In April 2020 in the USA, 13.6% of US adults reported symptoms of serious psychological distress, relative to 3.9% in 2018 (McGinty et al., 2020).

Thus, the aim of this project is to identify, track, and monitor trends of the populations at risk of major depressive disorder (MDD) and generalized anxiety disorder (GAD) during the COVID-19 pandemic. This article covers three main objectives: 1) describe the mental health trends (anxiety & depression) between May and August 2020, 2) compare the results with pre-COVID-19 results, and 3) identify risk factors associated with increased likelihood of high risk of MDD or GAD.

2. Method

2.1. Design

This report consists of repeated cross-sectional, national-level mental health screening conducted via computer-assisted phone interviews in four waves on a monthly basis (between May and August 2020). The full methodology and rationale were previously published as a study protocol article ‘as a pre-print (not yet peer-reviewed)’ (BinDhim et al., 2020).

2.2. Participants and recruitment

Adults aged 18 years and older from Saudi Arabia were recruited via a random phone number list generated by the Sharik Association for Health Research, a research participants’ database (Sharik Association for Health Research [SharikHealth], 2015). The Sharik database, of individuals interested in participating in health research, currently has more than 64,000 potential participants and is growing on a daily basis, covering the 13 administrative regions of Saudi Arabia (Sharik Association for Health Research [SharikHealth], 2015).

Participants were contacted by phone up to three times. If a participant did not respond, another potential participant with a similar demographic profile (age, sex, region) was invited. Each participant was eligible to participate once across the four waves.

2.3. Sample size

This surveillance system used a proportional quota sampling technique to achieve an equal distribution of participants, stratified by age, sex, and region within and across the 13 administrative regions of Saudi Arabia. We used two age groups based on the Saudi median adult age of 36 years (one group was between 18 to 36 years and the second group was over 37 years). This led to a quota of 52 for this study, which helped increase the diversity of the sample and reduced the risk of nonprobability sampling bias.

We calculated the sample size on the basis of the depth of the sub-analysis we needed to reach, which compared the age and sex groups across regions with a medium effect size of approximately 0.3 with 80% power and a 95% confidence level (Cohen, 2013). Thus, each quota required 78 participants and a total sample of 312 per region to form a grand total of 4,056 participants per wave. Once the quota sample was reached, participants with similar characteristics were not eligible to participate in the study. Quota sampling is an automated process with no human interference, as the sampling process is controlled automatically by the data collection system (BinDhim, 2012).
2.4. Questionnaire design & validation

The data collection included such general demographic variables as age, sex, region, educational level, and marital status. It also included COVID-19 categorizing variables, such as employment category (e.g. healthcare professional, security, etc.), and worries about getting COVID-19. In addition, other health-related risk factors, such as a history of chronic health conditions, obesity, and smoking, were collected.

The main mental health screening tool used here was the Patient Health Questionnaire (PHQ-9) (Becker, Al Zaid, & Al Faris, 2002; Kroenke & Spitzer, 2002; Kroenke, Spitzer, & Williams, 2001). PHQ-9 was selected over other depression screening tools because 1) it has been validated for use among various age groups, including adolescents, adults, and the elderly, (BinDhim et al., 2016, 2015); and 2) it has been shown to have consistent performance regardless of the mode of administration (e.g. patient self-report, interviewer-administered in person or by telephone, or touchscreen devices). (BinDhim et al., 2016, 2015; Fann et al., 2009) 3) PHQ-9 showed validity and reliability to screen for depression in a Saudi sample (AlHadi et al., 2017; Al-Qadhi et al., 2014; Becker et al., 2002). Moreover, 4) PHQ-9 has been used for mental health screening in various international surveys and surveillance systems (e.g. the CDC in the USA uses the PHQ-9 in the Behavioural Risk Factor Surveillance System and the National Health and Nutrition Examination Survey), which can also allow for international comparison (Reeves et al., 2011). Finally, PHQ-2, which uses a subset of PHQ-9 questions, was used in a national-level survey in Saudi Arabia in 2018 with cut-off point 3, with a methodology almost identical to that of this study, covering the 13 regions of Saudi Arabia and using an identical sampling technique that should allow for pre-COVID-19 comparison (Althumiri et al., 2018).

Finally, anxiety was measured using Generalized Anxiety Disorder-7 (GAD-7), which has also shown good validity and reliability in various studies (Spitzer, Kroenke, Williams, & Löwe, 2006). GAD-7 also demonstrated good validity in a general population screening, including in the Arabic language among the Saudi population (Alosaimi, Al-Sultan, Alghanmi, Almohameed, & Alqannas, 2014; Löwe et al., 2008; Plummer, Manea, Trepel, & McMillan, 2016; Sawaya, Atou, Hamadeh, Zeinoun, & Nahas, 2016).

After finalizing the first draft of the survey, we conducted linguistic validation via a focus group of eight participants, who were asked to discuss and answer the survey (excluding the previously validated screening tools 'PHQ-9 & GAD-7') as one group. According to the results of the focus group and feedback from the researchers and interviewers, the questionnaire was edited further until the final version of it was produced. Afterwards, in a pilot stage, 115 participants were interviewed by phone to assess internal consistency, and this stage showed high internal consistency for PHQ-9 (Cronbach’s alpha = 0.86) and GAD-7 (Cronbach’s alpha = 0.91). The average interview time was 7 minutes.

2.5. Outcome Measures

To determine the prevalence of the high risk of depression and anxiety in our sample, we used a score of more than 10, which in pooled estimates of 10 studies had the best trade-off between sensitivity, 0.89 (95% CI 0.75 to 0.96), and specificity, 0.89 (95% CI 0.79 to 0.94) (Manea, Gilbody, & McMillan, 2012).

In terms of GAD-7, pooled sensitivity and specificity values appeared acceptable at a cut-off point of 8 [sensitivity: 0.83 (95% CI 0.71–0.91), specificity: 0.84 (95% CI 0.70–0.92)], and cut-off scores between 7 and 10 also had similar pooled estimates of sensitivity/specificity (Plummer et al., 2016). In addition, on the GAD-7 anxiety measure, a score of 10 or more showed the optimum cut-off in the literature and in previous studies on Saudi populations (Alosaimi et al., 2014; Spitzer et al., 2006).

Finally, worries about getting the COVID-19 disease were measured with a 5-point Likert-scale question, rated from 1 (not worried at all) to 5 (extremely worried).

2.6. Statistical analysis

Prevalence data were weighted to equal the adult population in Saudi Arabia, according to the General Authority of Statistics Censuses Report. Quantitative variables are presented by mean and SD if they have a normal distribution or by median and range, as appropriate, and are compared using a t-test. Qualitative variables are presented as percentages and CIs and compared using Pearson’s $\chi^2$ test. Logistic regression adjusted for age and sex as the main non-modifiable demographical variables and non-adjusted was used for multivariate analysis to explore risk factors associated with being at risk of MDD or GAD. As this study used automated electronic data collection, there are no missing values; the QPlatform also includes a data integrity check to prevent users from entering invalid data (BinDhim, 2012).

2.7. Ethical considerations

The ethics committee of the Sharik Association for Health Research approved this research project
(Approval no. 2020–1) according to the national research ethics regulations. Consent to participate was obtained verbally during the phone interviews with the participants and recorded on the data collection system.

### 2.8. Role of the funding source

This project is funded by King Abdulaziz City for Science and Technology (KACST); grant number (5–20-01-000-0001). The funder of the study had no role in data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### 3. Results

#### 3.1. Demographics

Across the four waves (May, June, July, August 2020), 16,513 participants completed the interviews, with an overall response rate of 81.3% (16,513/20,294). Table 1 shows the distribution of the sample across the waves by the main demographic variables. The mean age was 36.5, and the median age 36 (range between 18 and 90).

| Table 1. Participant demographics. |
|-----------------------------------|
|                         | Wave 1  |
|                         | n (%)   | Wave 2  |
|                         | n (%)   | Wave 3  |
|                         | n (%)   | Wave 4  |
|                         | n (%)   |

| Sex                          | Wave 1  | Wave 2  | Wave 3  | Wave 4  | All Waves  |
|------------------------------|---------|---------|---------|---------|------------|
| Male                         | 1989 (49.7) | 2083 (49.8) | 2058 (49.6) | 2092 (50.1) | 8222 (49.8) |
| Female                       | 2015 (50.3) | 2097 (50.2) | 2095 (50.4) | 2084 (49.9) | 8291 (50.2) |
| **Education Level**          |         |         |         |         |            |
| High school or less          | 1444 (36.1) | 1457 (34.9) | 1465 (35.3) | 1548 (37.1) | 5914 (35.8) |
| Undergraduate diploma        | 484 (12.1) | 456 (10.9) | 466 (11.2) | 443 (10.6) | 1849 (11.2) |
| Bachelor’s degree            | 1846 (46.1) | 2022 (48.4) | 1955 (47.1) | 1955 (46.8) | 7778 (47.1) |
| Postgraduate degree (Master’s/PhD) | 230 (5.7) | 245 (5.9) | 267 (6.4) | 230 (5.5) | 972 (5.9) |
| **Income Level**             |         |         |         |         |            |
| Less than 5000 SAR           | 629 (15.7) | 604 (14.4) | 689 (16.6) | 678 (16.2) | 2600 (15.7) |
| Between 5001 and 8000 SAR    | 687 (17.2) | 595 (14.2) | 668 (16.1) | 709 (17.0) | 2659 (16.1) |
| Between 8001 and 11000 SAR   | 619 (15.5) | 610 (14.6) | 664 (16.0) | 652 (15.6) | 2545 (15.4) |
| Between 11001 and 13000 SAR  | 486 (12.1) | 551 (13.2) | 502 (12.1) | 539 (12.9) | 2078 (12.6) |
| Between 13001 and 16000 SAR  | 542 (13.5) | 628 (15.0) | 539 (13.5) | 603 (14.4) | 2332 (14.1) |
| More than 16000 SAR          | 1041 (26.0) | 1192 (28.5) | 1071 (25.8) | 995 (23.8) | 4299 (26.0) |
| **Regions**                  |         |         |         |         |            |
| Asir                         | 321 (8.0) | 322 (7.7) | 321 (7.7) | 321 (7.7) | 1285 (7.8) |
| Baha                         | 316 (7.9) | 311 (7.4) | 314 (7.6) | 320 (7.7) | 1261 (7.6) |
| Eastern region               | 314 (7.8) | 322 (7.7) | 323 (7.8) | 324 (7.8) | 1283 (7.8) |
| Jizan                        | 312 (7.8) | 321 (7.7) | 321 (7.7) | 321 (7.7) | 1278 (7.7) |
| Al Jouf                      | 288 (7.2) | 318 (7.6) | 320 (7.7) | 326 (7.8) | 1252 (7.6) |
| Madinah                      | 321 (8.0) | 325 (7.8) | 316 (7.6) | 321 (7.7) | 1283 (7.8) |
| Makka                        | 325 (8.1) | 325 (7.8) | 323 (7.8) | 320 (7.7) | 1293 (7.8) |
| Najran                       | 303 (7.6) | 322 (7.7) | 321 (7.7) | 320 (7.7) | 1266 (7.7) |
| Northern border              | 318 (7.9) | 318 (7.6) | 321 (7.7) | 318 (7.6) | 1275 (7.7) |
| Qassim                       | 309 (7.7) | 328 (7.8) | 320 (7.7) | 320 (7.7) | 1277 (7.7) |
| Riyadh                       | 301 (7.5) | 323 (7.7) | 320 (7.7) | 324 (7.8) | 1268 (7.7) |
| Tabuk                        | 382 (7.1) | 319 (7.6) | 310 (7.5) | 319 (7.6) | 1231 (7.5) |
| **Marital Status**           |         |         |         |         |            |
| Never married                | 1548 (38.7) | 1641 (39.3) | 1611 (38.8) | 1582 (37.9) | 6382 (38.6) |
| Married                      | 2196 (54.8) | 2269 (54.3) | 2279 (54.9) | 2327 (55.7) | 9071 (54.9) |
| Divorced/Separated           | 169 (4.2) | 165 (3.9) | 152 (3.7) | 163 (3.9) | 649 (3.9) |
| Widowed                      | 91 (2.3) | 105 (2.5) | 111 (2.7) | 104 (2.5) | 411 (2.5) |
| **Work Status**              |         |         |         |         |            |
| Employed                     | 1579 (39.4) | 1723 (41.2) | 1638 (39.4) | 1678 (40.2) | 6618 (40.1) |
| Self-employed                | 179 (4.5) | 189 (4.5) | 170 (4.1) | 178 (4.3) | 716 (4.3) |
| Unemployed                   | 1121 (28.0) | 1081 (25.9) | 1117 (26.9) | 1166 (27.9) | 4485 (27.2) |
| Student                      | 816 (20.4) | 853 (20.4) | 907 (21.8) | 849 (20.3) | 3425 (20.7) |
| Retired                      | 309 (7.7) | 334 (8.0) | 321 (7.7) | 305 (7.3) | 1269 (7.7) |
| **Grand Total**              | 4004     | 4180     | 4153     | 4176     | 16513      |

### 3.2. Health status and risk factors

Table 2 shows the distribution of health status and other risk factors by waves.

#### 3.3. Mental health risks

The weighted national prevalence of people at risk of MDD (PHQ-9 – Cut-Off above 10) was 14.9% overall and 13.8%, 13.6%, 16.8%, and 15.3% in waves 1, 2, 3, and 4, respectively. The weighted national prevalence of people at risk of GAD (GAD-7 – Cut-Off above 10) was 11.4% overall and 10.9%, 10.7%, 12.4%, and 11.7% in Waves 1, 2, 3, and 4, respectively. The weighted national proportion of individuals at risk of MDD and GAD at the same time was 7.4% overall and 6.6%, 6.2%, 8.1%, and 8.4% in Waves 1, 2, 3, and 4, respectively. The weighted national proportion of
individuals at risk of one or both conditions was 19.0% overall. Table 3 shows the prevalence of people at risk of MDD, GAD, and both disorders by sex in the study sample. Overall, there were significant differences between male and female participants in risk of MDD – χ² (1, N = 16,513) = 107.6, p < .001 – of GAD – χ² (1, N = 16,513) = 60.1, p < .001 – and of both disorders – χ² (1, N = 16,513) = 46.3, p < .001.

### 3.3.1. Comparison among waves

Chi-square analysis showed no significant differences in the proportions of participants at risk of MDD χ² (1, N = 8,176) = 0.059, p = .808 and of participants at risk of GAD χ² (1, N = 8,176) = 0.069, p = .793 between Wave 1 and Wave 2. However, there were significant differences in the proportions of participants at risk of MDD χ² (1, N = 8,289) = 16.90, p < .001 and of participants at risk of GAD χ² (1, N = 8,289) = 5.84, p = .016 between Wave 2 and Wave 3. The differences between Wave 3 and Wave 4 were not significant, risk of MDD χ² (1, N = 8,273) = 3.45, p = .063 and of participants at risk of GAD χ² (1, N = 8,273) = 1.22, p = .268.

### 3.4. Comparison with pre-COVID-19 trends

In 2018, based on PHQ-2, the weighted prevalence of participants at risk out of 3,698 participants (their mean age was 36.9 years and 51.2% were males) was 12.5% (Althumiri et al., 2018). In this study, the weighted national prevalence of people at risk of MDD (PHQ-2 – Cut-Off 3 and above) was 21.4% overall, and 21.5%, 20.3%, 22.3%, and 21.3% in Waves 1, 2, 3, and 4, respectively.

### 3.5. Risk factors associated with being at risk of MDD and GAD

As shown in Table 4, having a chronic health condition, working completely from home, obesity, cigarette smoking, having worries about getting COVID-19, and living with an elderly person were significantly associated with being at risk of MDD and GAD.

### 4. Discussion

This study presents the results of the Saudi Arabia Mental Health Surveillance System during the
Table 3. Prevalence of people at risk of MDD, GAD, and both disorders by sex in the study sample.

|                      | Wave 1 n | Wave 2 n | Wave 3 n | Wave 4 n | All Waves n |
|----------------------|----------|----------|----------|----------|-------------|
|                      | Female   | Male     | Total    | Female   | Male        | Total    |
| PHQ-9 (Cut-Off above 10) |          |          |          |          |             |          |
| At risk of MDD       | 321 (15.9) | 249 (12.5) | 570 (14.2) | 333 (15.9) | 225 (10.8) | 558 (13.3) |
| Not at risk of MDD   | 1694 (84.1) | 1740 (87.5) | 3434 (85.8) | 1764 (84.1) | 1858 (89.2) | 3622 (86.7) |
| GAD-7 (Cut-Off above 10) |          |          |          |          |             |          |
| At risk of GAD       | 269 (13.3) | 222 (11.2) | 491 (12.3) | 279 (13.3) | 184 (8.8) | 463 (11.1) |
| Not at risk of GAD   | 1746 (86.7) | 1767 (88.8) | 3513 (87.7) | 1818 (86.7) | 1899 (91.2) | 3717 (88.9) |
| Combined Risk of MDD and GAD |          |          |          |          |             |          |
| Yes                  | 260 (12.9) | 125 (6.3) | 395 (9.8) | 274 (13.1) | 107 (5.1) | 381 (8.8) |
| No                   | 1755 (87.1) | 1864 (93.7) | 3619 (90.2) | 1823 (86.9) | 1976 (94.9) | 3799 (86.2) |
| Grand Total          | 2015      | 1989      | 4004      | 2097      | 2083       | 4180      |

COVID-19 pandemic between May and August 2020. The results showed that the risk of MDD and GAD was significantly higher than PHQ-9, indicating that the prevalence of depression and anxiety was higher in the pandemic period compared to the pre-COVID-19 period. However, the prevalence of depression and anxiety was higher in the pandemic period compared to the pre-COVID-19 period. The results showed that the risk of MDD and GAD was significantly higher than PHQ-9, indicating that the prevalence of depression and anxiety was higher in the pandemic period compared to the pre-COVID-19 period.
and period of the COVID-19 pandemic. The three studies found a significant increase from the baseline in 2018 (in the UK, from 18.9% in 2018 to 27.3% in April 2020; in the USA, from 3.9% in 2018 to 13.6% in April 2020) (McGinty et al., 2020; Pierce et al., 2020). The third study used PHQ-2 to compare between data from 2019 and 2020 in the USA and found that the risk increased

| Variables | Crude OR (95% CI) (p-value) | Adjusted OR (95% CI) (p-value)* |
|-----------|-----------------------------|--------------------------------|
| **Risk of MDD (PHQ-9 Cut-Off above 10)** | | |
| Have Chronic Health Condition (Without Depression & Anxiety) | Reference | Reference |
| No | 1.29 (1.17–1.41) (<0.001) | 1.66 (1.50–1.84) (<0.001) |
| Yes | | |
| Going Out for Work during COVID-19 ** | | |
| Yes, daily | Reference | Reference |
| Yes, sometimes | 0.97 (0.82–1.14) (0.743) | 1.04 (0.88–1.232) (0.598) |
| Not at all | | |
| Healthcare Worker | Reference | Reference |
| No | 0.83 (0.70–0.98) (0.034) | 0.84 (0.71–1.00) (0.051) |
| Yes | | |
| Obesity (BMI≥30) | Reference | Reference |
| No | 1.11 (1.01–1.23) (0.031) | 1.22 (1.10–1.35) (<0.001) |
| Yes | | |
| Cigarette Smoking | Reference | Reference |
| Non-Smoker | Reference | Reference |
| Daily smoker | 1.11 (0.97–1.28) (0.109) | 1.52 (1.31–1.77) (<0.001) |
| Occasional (social) smoker | 1.22 (1.06–1.42) (0.003) | 1.50 (1.29–1.74) (<0.001) |
| Worries about Getting COVID-19 | Reference | Reference |
| 1 Not worried at all | 0.95 (0.83–1.08) (0.484) | 0.91 (0.80–1.04) (0.208) |
| 2 | 1.04 (0.92–1.18) (0.445) | 0.99 (0.88–1.13) (0.988) |
| 3 | 1.41 (1.22–1.63) (<0.001) | 1.40 (1.21–1.62) (<0.001) |
| 4 | 1.89 (1.64–2.18) (<0.001) | 1.84 (1.59–2.12) (<0.001) |
| 5 Extremely worried | | |
| Living with Children | Reference | Reference |
| No | 0.88 (0.80–0.97) (0.013) | 0.87 (0.79–0.96) (0.010) |
| Yes | | |
| Living with Elderly Person | Reference | Reference |
| No | 1.31 (1.19–1.44) (<0.001) | 1.30 (1.18–1.43) (<0.001) |
| Yes | | |
| Number of People Living in Same Home | Reference | Reference |
| 0–3 | 1.38 (1.20–1.57) (<0.001) | 1.37 (1.20–1.57) (<0.001) |
| 4–6 | 1.30 (1.14–1.40) (<0.001) | 1.26 (1.11–1.44) (<0.001) |
| 7+ | | |
| **Risk of GAD (GAD-7 Cut-Off of 10)** | | |
| Have Chronic Health Condition (Without Depression & Anxiety) | Reference | Reference |
| No | 1.42 (1.28–1.57) (<0.001) | 1.55 (1.38–1.74) (<0.001) |
| Yes | | |
| Going Out for Work during COVID-19 ** | | |
| Yes, daily | Reference | Reference |
| Yes, sometimes | 0.91 (0.76–1.09) (0.352) | 0.94 (0.79–1.13) (0.560) |
| Not at all | 1.30 (1.14–1.48) (<0.001) | 1.17 (1.02–1.35) (0.025) |
| Healthcare Worker | Reference | Reference |
| No | 0.80 (0.66–0.97) (0.025) | 0.82 (0.67–0.99) (0.048) |
| Yes | | |
| Obesity (BMI≥30) | Reference | Reference |
| No | 1.14 (1.02–1.27) (0.020) | 1.15 (1.03–1.29) (0.013) |
| Yes | | |
| Cigarette Smoking | Reference | Reference |
| Non-Smoker | Reference | Reference |
| Daily smoker | 1.39 (1.20–1.60) (<0.01) | 1.84 (1.57–2.15) (<0.001) |
| Occasional (social) smoker | 1.21 (1.03–1.43) (0.018) | 1.49 (1.25–1.76) (<0.001) |
| Worries about Getting COVID-19 | Reference | Reference |
| 1 Not worried at all | 0.71 (0.61–0.84) (0.001) | 0.70 (0.60–0.82) (<0.001) |
| 2 | 0.96 (0.83–1.10) (0.562) | 0.92 (0.80–1.06) (0.300) |
| 3 | 1.60 (1.36–1.87) (<0.001) | 1.56 (1.34–1.83) (<0.001) |
| 4 | 2.30 (1.98–2.68) (<0.001) | 2.22 (1.91–2.58) (<0.001) |
| 5 Extremely worried | | |
| Living with Children | Reference | Reference |
| No | 0.92 (0.82–1.03) (0.152) | 0.92 (0.83–1.03) (0.177) |
| Yes | | |
| Living with Elderly Person | Reference | Reference |
| No | 1.22 (1.10–1.36) (<0.001) | 1.21 (1.09–1.34) (<0.001) |
| Yes | | |
| Number of People Living in Same Home | Reference | Reference |
| 0–3 | 1.36 (1.17–1.58) (<0.001) | 1.34 (1.15–1.56) (<0.001) |
| 4–6 | 1.42 (1.22–1.65) (<0.001) | 1.38 (1.19–1.61) (<0.001) |
| 7+ | | |

*Adjusted for age and sex; **unemployed and retired were excluded.
from 6.6% in 2019 to 23.5% in April 2020 (Twenge & Joiner, 2020). The overall risk in 2020 in Saudi Arabia is closer to that of the USA than that of the UK, generally. However, this is the first national-level study from a developing non-Western country to report such an increase in mental health risk during the COVID-19 pandemic.

However, the risk of both MDD and GAD increased significantly between Wave 2 (June 2020) and Wave 3 (July 2020), and the increase was sustained in Wave 4. We assume that the cause of this increase is complex, as it may be associated with the latency of mental health symptoms. In addition, the government increased the value-added tax (VAT) by 10%, from 5% to 15%, starting from 1st of July 2020, which may also have played a role in the increased risk.

This study found that having a chronic health condition, working completely from home, obesity, cigarette smoking, worries about getting COVID-19, and living with an elderly person were significantly associated with being at risk of MDD and GAD. This information is important to decision makers for understanding the psychological impact and identifying segments of the population who may need support and special help programs. The increase of the proportions of people at risk of MDD and/or GAD must be addressed also in terms of service accessibility, and more importantly, increasing awareness of mental health importance and its related stigma. Decision makers may also implement a periodic mental health screening programmes to capture future trends and build a historical database that may help in future emergencies. Finally, this study focused on the adult general population, and more focus is also needed on the youth, as they, too, are susceptible to developing mental health conditions.

The use of proportional quota (nonprobability) sampling provides more statistical power to detect changes, not only at national but also at regional levels, which further helps to stratify data in relation to the most affected regions and subpopulations to provide a more in-depth picture of the effects of COVID-19. However, we acknowledge that using nonprobability sampling has some risk of bias. Although we strived to obtain a large sample with larger coverage of the population, the quota sampling design may limit generalizability and representatives. However, the obtained sample fits the national adult age average and sex distribution and was weighted to fit the region’s distribution. Currently, the only way to conduct a random representative national survey in Saudi Arabia is via household interviews, but such a method is not possible under COVID-19 restrictions and curfews, and it is also costly to operate on a monthly basis. Therefore, this study also considered the cost of conducting a more cost-effective project via quota sampling. Finally, to improve the sampling accuracy, 52 strata were used to allow for inclusion of a more diverse sample. Although the sample was weighted to represent the adult population in Saudi Arabia, the generalizability of the results may still be affected by the nonprobability sampling used in this study.

5. Conclusion
This study presents the results of the Saudi Arabia Mental Health Surveillance System during the COVID-19 pandemic from May to August 2020. The results showed that the risks of MDD and GAD are relatively high. The results of this study will help decision makers understand the impact of the COVID-19 pandemic on the population’s mental health and customize support to the most-impacted subgroups.

Acknowledgments
The authors would like to express their gratitude and appreciation to KACST for providing the research grant for this study.
We also extend our thanks to Dr. Mohammad Alkelayah, Dr. Nahar Alazmi, and Dr. Rufaidah Aldabagh for their logistical and scientific support.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
This project is funded by King Abdulaziz City for Science and Technology (KACST); grant number (5-20-01-000-0001).

Author contributions
All authors provided major contributions to the conceptual design and development of this study protocol. Nora A Althumir and Mada H Bayouni supervised the data collection process. Nasser F BinDhim conducted the data analysis. All authors reviewed the data analysis process and provided feedback and suggestion for changes and modifications in a live meeting. Nasser F BinDhim wrote the first draft of the manuscript and all authors reviewed and approved the final manuscript.

Data availability statement
To comply with local regulations all national datasets from Saudi Arabia must be deposited to the National Health Research and Studies Portal. The data that support the findings of this study are available on request for researchers from the National Health Research and Studies Portal at: https://nhrsp.shc.gov.sa/
ORCID

Nasser F. BinDhím  http://orcid.org/0000-0001-8117-1044
Nora A. Alhumiri  http://orcid.org/0000-0002-8216-6097
Mada H. Basyouni  http://orcid.org/0000-0002-8905-8641
Asem A. Alageel  http://orcid.org/0000-0003-4885-9036
Salim Alghanam  http://orcid.org/0000-0001-5817-0481
Ada M. Al-Qunaibet  http://orcid.org/0000-0002-3193-2586
Rasha A. Almubarak  http://orcid.org/0000-0002-5051-5610
Nasr Ada Shahla  http://orcid.org/0000-0003-1808-2596
Nasser Yasser Ad-Db'bagh  http://orcid.org/0000-0001-5583-131X

References

Alenazi, T. H., BinDhím, N. F., Alenazi, M. H., Tamim, H., Almagradi, R. S., Aljohani, S. M., & Alqahtani, S. A. (2020). Prevalence and predictors of anxiety among healthcare workers in Saudi Arabia during the COVID-19 pandemic. Journal of Infection and Public Health, 13(11), 1645–1651.

Al-Gelban, K. S., Al-Amri, H. S., & Mostafa, O. A. (2009). Prevalence of depression, anxiety and stress as measured by the depression, anxiety, and stress scale (DASS-42) among secondary school girls in Abha, Saudi Arabia. Sultan Qaboos University Medical Journal, 9(2), 140.

AlHadi, A. N., AlAteeq, D. A., Al-Sharif, E., Bawazee, H. M., Alenazi, H., AlShomari, A. T., … AlOwaybil, R. (2017). An arabic translation, reliability, and validation of Patient Health Questionnaire in a Saudi sample. Annals of General Psychiatry, 16(1), 32.

Alosaimi, F. D., Al-Sultan, O. A., Alghamdi, Q. A., Almohaimee, I. K., & Alqannas, S. I. (2014). Gender-specific differences in depression and anxiety symptoms and help-seeking behavior among gastroenterology patients in Riyadh, Saudi Arabia. Neurosciences, 19(3), 203.

Al-Qadhi, W., Ur Rahman, S., Ferwana, M. S., & Abdalmajeed, I. A. (2014). Adult depression screening in Saudi primary care: Prevalence, instrument and cost. BMC Psychiatry, 14(1), 190.

Althumiri, N. A., Alammar, N. S., Almubark, R. A., Alnofal, F. A., Alkhams, D. J., Alharbi, L. S., & Alqahtani, A. S. (2018). The national survey of health, diet, physical activity and supplements among adults in Saudi Arabia. Food and Drug Regulatory Science Journal, 1(1), 1.

Arroll, B., Goodyear-Smith, F., Crengle, S., Gunn, J., Kerse, N., Fishman, T., … Hatcher, S. (2010). Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. The Annals of Family Medicine, 8(4), 348–353.

Becker, S., Al Zaid, K., & Al Faris, E. (2002). Screening for somatization and depression in Saudi Arabia: A validation study of the PHQ in primary care. The International Journal of Psychiatry in Medicine, 32(3), 271–283.

BinDhím, N. F. (2012). Smart health project. https://shproject.net/

BinDhím, N. F., Alenazi, E. M., Aljadhey, H., Basyouni, M. H., Kowalski, S. R., Pont, L. G., & Alhwass, T. M. (2016). Does a mobile phone depression-screening app motivate mobile phone users with high depressive symptoms to seek a health care professional’s help? Journal of Medical Internet Research, 18(6), e156.

BinDhím, N. F., Shamam, A. M., Trevena, L., Basyouni, M. H., Pont, L. G., & Alhwass, T. M. (2015). Depression screening via a smartphone app: Cross-country user characteristics and feasibility. Journal of the American Medical Informatics Association, 22(1), 29–34.

BinDhím, N. F. A. N., Basyouni, M. H., Alageel, A. A., Alghnaim, S., Al-Qunaibet, A. M., Almubarak, R. A., … Ad-Dab’bagh, Y. (2020). A Mental Health Surveillance System for the General Population During the COVID-19 Pandemic: Protocol for a Multivariate Cross-sectional Survey Study.” JMIR research protocols, 9(11), e23748.

Brody, D. J., Pratt, L. A., & Hughes, J. P. (2018). Prevalence of depression in adults aged 20 and over: United States, 2013–2016. NCHS Data Brief, no 303.

Hyattsville, MD: National Center for Health Statistics.

Cohen, J. (2013). Statistical power analysis for the behavioral sciences. New York, NY: Routledge.

Colpe, L. J., Freeman, E. J., Strine, T. W., Dhingra, S., McGuire, L. C., Elam-Evans, L. D., & Perry, G. S. (2010). Public Health Surveillance for Mental Health. Preventing Chronic Disease, 7(1), 1.

Ebrahim, S. H., & Memish, Z. A. (2020). Saudi Arabia’s drastic measures to curb the COVID-19 outbreak: Temporary suspension of the Umrah pilgrimage. Journal of Travel Medicine, 27(3), taa029.

Fann, J. R., Berry, D. L., Wolpin, S., Austin-Seymour, M., Bush, N., Halpenny, B., … McCorkle, R. (2009). Depression screening using the Patient Health Questionnaire-9 administered on a touch screen computer. Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer, 18(1), 14–22.

Holmes, E. A., O’Connor, R. C., Perry, V. H., Tracey, I., Wessely, S., Arseneault, L., & Bullmore, E. (2020). Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. The Lancet Psychiatry, 7(6), 547–560.

Ibrahim, N., Dania, A.-K., Lamis, E.-K., Ahd, A.-H., & Asali, D. (2013). Prevalence and predictors of anxiety and depression among female medical students in King Abdulaziz University, Jeddah, Saudi Arabia. Iranian Journal of Public Health, 42(7), 726.

Javakhshivili, J. D., Ardino, V., Bragesjö, M., Kazlauskas, E., Olff, M., & Schäfer, I. (2020). Trauma-informed responses in addressing public mental health consequences of the COVID-19 pandemic: Position paper of the European Society for Traumatic Stress Studies (ESTSS). European Journal of Psychotraumatology, 11(1), 1780782.

Kroenke, K., & Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, 32(9), 509–515.

Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613.

Lee, S. A. (2020). How much “Thinking” about COVID-19 is clinically dysfunctional? Brain, Behavior, and Immunity, 87, 97–98.

Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical Care, 46(3), 266–274.

Mance, L., Gilbody, S., & McMillan, D. (2012). Optimal cut-off score for diagnosing depression with the Patient
Health Questionnaire (PHQ-9): A meta-analysis. Canadian Medical Association Journal, 184(3), E191–E196. McGinty, E. E., Presskreischer, R., Han, H., & Barry, C. L. (2020). Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA, 324(1), 93. Norris, F. H. (2006). Methods for disaster mental health research. New York, NY: Guilford Press. Olff, M., Bakker, A., Frewen, P., Aakvaag, H., Ajdukovic, D., Brewer, D., … Schnyder, U. (2020). Screening for consequences of trauma—an update on the global collaboration on traumatic stress. European Journal of Psychotraumatology, 11(1), 1752504. Pierce, M., Hope, H., Ford, T., Hatch, S., Hotopf, M., John, A., … Abel, K. M. (2020). Mental health before and during the COVID-19 pandemic: A longitudinal probability sample survey of the UK population. The Lancet Psychiatry, 7(10), 883–892. Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic metaanalysis. General Hospital Psychiatry, 39, 24–31. Porta, M. (2014). A dictionary of epidemiology. Oxford: Oxford university press. Reeves, W. C., Pratt, L. A., Thompson, W., Ahluwalia, I. B., Dhingra, S. S., McKnight-Eily, L. R., … & Safran, M. A. (2011). Mental illness surveillance among adults in the United States. Hyattsville, MD: Centers for Disease Control and Prevention. Sawaya, H., Atou, M., Hamadeh, A., Zeinoun, P., & Nahas, Z. (2016). Adaptation and initial validation of the Patient Health Questionnaire–9 (PHQ-9) and the Generalized Anxiety Disorder–7 Questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample. Psychiatry Research, 239, 245–252. Serafini, G., Parmigiani, B., Amerio, A., Aguglia, A., Sher, L., & Amore, M. (2020). The psychological impact of COVID-19 on the mental health in the general population. QJM: An International Journal of Medicine, 113(8), 531–537. Sharik Association for Health Research [SharikHealth]. (2015). https://sharikhealth.com/ Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. Thacker, S. B., Qualters, J. R., & Lee, L. M. (2012). Control CfD, Prevention. Public health surveillance in the United States: Evolution and challenges. MMWR Surveill Summ, 61(Suppl), 3–9. Twenge, J. M., & Joiner, T. E. (2020). US Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID-19 pandemic. Depression and Anxiety, 37(10), 954–956. World Health Organization. (2017). Depression and other common mental disorders: Global health estimates. Geneva: Author. Yezli, S., & Khan, A. (2020). COVID-19 social distancing in the Kingdom of Saudi Arabia: Bold measures in the face of political, economic, social and religious challenges. Travel Medicine and Infectious Disease, 37, 101692.